Signifor (pasireotide) is indicated for adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.
Signifor (pasireotide) intramuscular injection is indicated for adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA).
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
To contact us in your country of residence, please click here